The Experts below are selected from a list of 276 Experts worldwide ranked by ideXlab platform
Michiaki Mishima - One of the best experts on this subject based on the ideXlab platform.
-
pulmonary embolism due to internal jugular vein thrombosis in a patient with non small cell lung cancer receiving bevacizumab
International Journal of Clinical Oncology, 2011Co-Authors: Yosuke Togashi, Katsuhiro Masago, Koji Tamai, Yuichi Sakamori, Michiaki MishimaAbstract:Internal jugular vein thrombosis is much less common than deep venous thrombosis of lower limbs and is generally caused by an indwelling venous catheter or otological infection. Several cases of internal jugular vein thrombosis associated with malignancy have been also reported. Bevacizumab, a monoclonal neutralizing antibody against vascular endothelial growth factor, has shown benefits in the treatment of many types of malignancy and its use is increasing. Serious adverse effects, however, are associated with the use of bevacizumab, including venous thromboembolism. In this article, we present a rare case of non-small cell lung cancer complicated by pulmonary embolism due to internal jugular vein thrombosis associated with bevacizumab.
Yosuke Togashi - One of the best experts on this subject based on the ideXlab platform.
-
pulmonary embolism due to internal jugular vein thrombosis in a patient with non small cell lung cancer receiving bevacizumab
International Journal of Clinical Oncology, 2011Co-Authors: Yosuke Togashi, Katsuhiro Masago, Koji Tamai, Yuichi Sakamori, Michiaki MishimaAbstract:Internal jugular vein thrombosis is much less common than deep venous thrombosis of lower limbs and is generally caused by an indwelling venous catheter or otological infection. Several cases of internal jugular vein thrombosis associated with malignancy have been also reported. Bevacizumab, a monoclonal neutralizing antibody against vascular endothelial growth factor, has shown benefits in the treatment of many types of malignancy and its use is increasing. Serious adverse effects, however, are associated with the use of bevacizumab, including venous thromboembolism. In this article, we present a rare case of non-small cell lung cancer complicated by pulmonary embolism due to internal jugular vein thrombosis associated with bevacizumab.
Wilko Grolman - One of the best experts on this subject based on the ideXlab platform.
-
Bilateral cochlear implantation in children: A systematic review and best-evidence synthesis
Laryngoscope, 2014Co-Authors: M J W Lammers, V E C Pourier, Geert J M G Van Der Heijden, Wilko GrolmanAbstract:Objectives/Hypothesis To evaluate the effectiveness of bilateral cochlear implantation over unilateral implantation in children with sensorineural hearing loss. Data Sources Pubmed, Embase, and Web of Science. Review Methods All studies comparing a bilateral cochlear implant group with a unilateral implant group were included. Results Twenty-one studies compared a bilateral cochlear implant group with a unilateral group. No randomized trials were identified. Due to the clinical heterogeneity, statistical pooling was not feasible and a best-evidence synthesis was performed. The results of this best-evidence synthesis indicate the positive effect of the second implant for especially sound localization and possibly for preverbal communication and language development. There was insufficient evidence to make a valid comparison between bilateral implantation and a bimodal fitting. Conclusion Although randomized trials are lacking, the results of our best-evidence synthesis indicate that the second cochlear implant might be especially useful in sound localization and possibly also in language development. Level of Evidence Laryngoscope, 124:1694-1699, 2014 © 2014 The American Laryngological, Rhinological and Otological Society, Inc.
Katsuhiro Masago - One of the best experts on this subject based on the ideXlab platform.
-
pulmonary embolism due to internal jugular vein thrombosis in a patient with non small cell lung cancer receiving bevacizumab
International Journal of Clinical Oncology, 2011Co-Authors: Yosuke Togashi, Katsuhiro Masago, Koji Tamai, Yuichi Sakamori, Michiaki MishimaAbstract:Internal jugular vein thrombosis is much less common than deep venous thrombosis of lower limbs and is generally caused by an indwelling venous catheter or otological infection. Several cases of internal jugular vein thrombosis associated with malignancy have been also reported. Bevacizumab, a monoclonal neutralizing antibody against vascular endothelial growth factor, has shown benefits in the treatment of many types of malignancy and its use is increasing. Serious adverse effects, however, are associated with the use of bevacizumab, including venous thromboembolism. In this article, we present a rare case of non-small cell lung cancer complicated by pulmonary embolism due to internal jugular vein thrombosis associated with bevacizumab.
Koji Tamai - One of the best experts on this subject based on the ideXlab platform.
-
pulmonary embolism due to internal jugular vein thrombosis in a patient with non small cell lung cancer receiving bevacizumab
International Journal of Clinical Oncology, 2011Co-Authors: Yosuke Togashi, Katsuhiro Masago, Koji Tamai, Yuichi Sakamori, Michiaki MishimaAbstract:Internal jugular vein thrombosis is much less common than deep venous thrombosis of lower limbs and is generally caused by an indwelling venous catheter or otological infection. Several cases of internal jugular vein thrombosis associated with malignancy have been also reported. Bevacizumab, a monoclonal neutralizing antibody against vascular endothelial growth factor, has shown benefits in the treatment of many types of malignancy and its use is increasing. Serious adverse effects, however, are associated with the use of bevacizumab, including venous thromboembolism. In this article, we present a rare case of non-small cell lung cancer complicated by pulmonary embolism due to internal jugular vein thrombosis associated with bevacizumab.
